Killer Angel
A boutique cross with a memorable name and very little verifiable data behind the marketing claims.
Killer Angel is a niche strain with a striking name and almost no independent data behind it. What you'll find online is mostly seedbank copy and a handful of user reviews — no lab-verified chemotype averages, no peer-reviewed work, and lineage claims that vary by source. Treat THC numbers, terpene profiles, and effect descriptions as marketing until your specific batch has a COA. If you like the plant, grow it on its own merits, not the legend.
Overview
Killer Angel is a cannabis variety circulated primarily through small seedbanks and dispensary menus rather than through any formally documented breeding program. Unlike widely studied cultivars such as OG Kush or Blue Dream, Killer Angel does not appear in published chemotyping datasets or government cultivar registries that we can verify No data.
What exists is essentially: vendor descriptions, a small number of grower reports, and user reviews on consumer sites. None of these are evidence in a scientific sense. If you're researching this strain to make a buying or growing decision, the honest summary is that almost everything claimed about it is unverified.
Chemistry: cannabinoids and terpenes
There is no published lab dataset for Killer Angel that we could locate. Vendor pages typically claim THC in the high teens to low 20s percent range and negligible CBD, which is unremarkable and reflects the dominant chemotype I (THC-dominant) profile of most modern hybrids [1] Weak / limited.
Terpene claims vary by listing — some cite myrcene-dominant profiles, others caryophyllene or limonene. Without batch-level certificates of analysis (COAs), these are guesses. Importantly, research shows terpene profiles vary dramatically between grows of the same named cultivar depending on phenotype selection, environment, and harvest timing [2][3] Strong evidence. The 'dominant terpene' of any given Killer Angel flower you buy is the dominant terpene of that batch, not of the name on the label.
Ignore the long-running folklore that myrcene above 0.5% 'unlocks' couch-lock or that any single terpene threshold reliably predicts effects — that claim originated in popular cannabis writing and has never been demonstrated in controlled human studies [4] Disputed.
Reported effects
User reports for Killer Angel describe a relaxing, body-leaning high with euphoric onset — descriptions that are essentially interchangeable with hundreds of other indica-leaning hybrids Anecdote.
There is no strain-specific clinical evidence for Killer Angel. No trials, no observational studies, no symptom-tracking app datasets large enough to isolate it. Any claim that this strain specifically treats anxiety, pain, insomnia, or anything else is folklore, not medicine No data.
More broadly, the assumption that a strain name predicts effects is itself shaky. A 2015 genetic analysis found that commercial strain names frequently do not correspond to consistent genetic identity — samples sold under the same name can be more genetically distinct than samples sold under different names [5] Strong evidence. The indica/sativa dichotomy, often used to predict 'body vs. head' effects, has been repeatedly criticized as having little chemical or pharmacological basis [3][6] Strong evidence.
Lineage
Reported lineage for Killer Angel varies between vendors and is disputed Disputed. Some listings describe it as a cross involving Killer Queen and an unnamed kush; others tie it to Angel-line genetics. We could not locate a primary breeder statement with verifiable provenance (no dated breeder release, no preserved seed-pack documentation in archives we trust).
This is common for boutique strains. Without breeder records, lineage claims are essentially oral tradition. If a specific lineage matters to you (for example, you're trying to avoid a parent you don't tolerate), don't rely on the name — ask the vendor for documentation, and recognize that even with documentation, the seed line and the clone line of any 'strain' diverge over years.
Cultivation basics
Growers reporting on Killer Angel describe an 8–9 week flowering window indoors, moderate stretch, and dense flower formation typical of kush-influenced hybrids Anecdote. These figures are consistent with most modern indoor hybrids and should not be treated as cultivar-specific guidance.
General cultivation principles that are well-supported:
- Cannabinoid and terpene yield depends heavily on light intensity (PPFD), VPD management, and harvest timing [2] Strong evidence.
- Late-flower temperature drops and reduced light intensity can preserve volatile terpenes, which degrade with heat and UV exposure Weak / limited.
- Phenotype hunting matters more than the name on the pack — even within a single seed batch, plants can differ substantially in chemistry and morphology [5] Strong evidence.
If you grow Killer Angel, grow several seeds, select the phenotype you like, and clone it. The 'Killer Angel' in your garden will become your Killer Angel — that's how cultivars actually propagate in practice.
Marketing vs. reality
Marketing claims you'll see: specific THC percentages, named dominant terpenes, confident lineage charts, and effect promises ('crushes anxiety,' 'perfect for sleep').
Reality: None of these are verifiable for Killer Angel from independent sources. The chemistry of any given batch can only be known from that batch's COA. Effects vary by individual, dose, tolerance, set, and setting — not by strain name alone [6] Strong evidence. Lineage stories without breeder documentation are stories.
This isn't unique to Killer Angel. It applies to most strains with cool names and thin paper trails. The useful question isn't 'is Killer Angel good?' — it's 'does this specific jar, with this specific COA, from this specific grower, deliver what I want?'
Sources
- Peer-reviewed Hazekamp A, Fischedick JT. Cannabis — from cultivar to chemovar. Drug Testing and Analysis. 2012;4(7-8):660-667.
- Peer-reviewed Chandra S, Lata H, ElSohly MA, et al. Cannabis cultivation: methodological issues for obtaining medical-grade product. Epilepsy & Behavior. 2017;70(Pt B):302-312.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.
- Peer-reviewed Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-1364.
- Peer-reviewed Sawler J, Stout JM, Gardner KM, et al. The genetic structure of marijuana and hemp. PLOS ONE. 2015;10(8):e0133292.
- Peer-reviewed Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. 2016;1(1):44-46.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Blue Dream — California's most-sold sativa-dominant hybrid, famous for balanced effects, easy growing,...
- OG Kush — The hazy-origin California strain that became the genetic backbone of modern American cann...